About 300 reports

  • BONE METASTASIS - PIPELINE BY LIVZON MABPHARM INC, H2 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019 (CONTD..1), H2 2019

DENOSUMAB BIOBETTER - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description denosumab biobetter Livzon MabPharm Inc NA NA Mechanism Of Action R& D Progress Denosumab biobetter (LZM-##) is under development for

  • Healthcare
  • Monoclonal Antibody
  • Prostate Cancer
  • Therapy
  • Amgen Inc.
  • PEMPHIGUS VULGARIS - PIPELINE BY IBIO INC, H2 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES

THE MOLECULES DEVELOPED BY COMPANIES IN PHASE III, PHASE II, PHASE I, IND/ CTA FILED, PRECLINICAL, DISCOVERY AND UNKNOWN STAGES ARE ##, ##, ##, ##, ##, ## AND ## RESPECTIVELY.

  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • Principia Biopharma Inc.

April ##, 2017, ##:## - ##:## p. m.

  • Healthcare
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative
  • PIPELINE BY MABTECH LTD, H2 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019

EACH UNIT IS COMPRISED OF ONE COMMON SHARE OF THE COMPANY AND ONE-HALF OF ONE COMMON SHARE PURCHASE WARRANT OF THE COMPANY.

  • Healthcare
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • follicle stimulating hormone biobetter - Drug Profile
  • Male Infertility - Pipeline by Aprilbio Co Ltd, H2 2019

The molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are ##, ##, ## and ## respectively.

  • Genitourinary System Disease
  • Healthcare
  • World
  • Product Initiative
  • Cadila Healthcare Ltd
  • CHRONIC URTICARIA OR HIVES - PIPELINE BY BIORALIX BV, H2 2019
  • CHRONIC URTICARIA OR HIVES - PIPELINE BY ALLAKOS INC, H2 2019

NA : Not Available Source: Global Markets Direct OMALIZUMAB BIOBETTER - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description OMALIZUMAB BIOBETTER BIORALIX BV NA NA Mechanism Of Action R& D Progress OMALIZUMAB

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018

NARA-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description NARA-## ANAVEON AG NA NA NARA-## IS UNDER DEVELOPMENT FOR THE TREATMENT OF MELANOMA, KIDNEY CANCER AND LUNG CANCER.

  • Healthcare
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Philogen S.p.A.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019 (CONTD..4), H2 2019
  • WOMEN INFERTILITY - DORMANT PROJECTS, H2 2019 (CONTD..1), H2 2019

FOLLICLE STIMULATING HORMONE (FSH) BIOBETTER MAY INCREASE BOTH OOCYTE NUMBER AND QUALITY IN MANY DIFFERENT TYPES OF INFERTILITY.

  • Genitourinary System Disease
  • Healthcare
  • Pharmaceutical
  • Company
  • Product Initiative
  • GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S GRANULOMATOSIS) - PIPELINE BY IBIO INC, H2 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019

NA : Not Available Source: Global Markets Direct RITUXIMAB BIOBETTER - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description RITUXIMAB BIOBETTER IBIO INC NA NA R& D Progress Research and Development Brief Licensing and C

  • Healthcare
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

The offering was subscribed to by one or more subscribers acceptable to the company in Ontario, British Columbia, Alberta, Saskatchewan and Manitoba.

  • Healthcare
  • Medical Biotechnology
  • Canada
  • Deals & Alliance
  • PlantForm Corporation

GlobalData HanAll Biopharma Co Ltd reported one pharmaceuticals & healthcare deal worth $## million in YTD 2018.

  • Biopharmaceutical
  • Healthcare
  • South Korea
  • M&A
  • HanAll Biopharma Co., Ltd.
  • SFR-9350 - DRUG PROFILE

Patients were randomly assigned in a ##:## ratio to receive oral febuxostat for ## months or not.

  • Chronic Disease
  • Healthcare
  • China
  • United States
  • Product Initiative
  • Deal Rationale
  • Jan 25, 2018: Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018

ATNM provides mab expension and biobetters development in stratergical platform.

  • Cancer
  • Healthcare
  • United States
  • Company
  • Actinium Pharmaceuticals, Inc.
  • KIDNEY TRANSPLANT REJECTION - PIPELINE BY MABTECH LTD, H2 2019

MABTECH LIMITED IS DEVELOPING BASILIXIMAB BIOBETTER (STI-##) FOR THE PROPHYLAXIS OF ACUTE ORGAN REJECTION IN PATIENTS RECEIVING KIDNEY TRANSPLANTATION.

  • Health Services
  • Healthcare
  • Monoclonal Antibody
  • United States
  • Product Initiative

Alpha-## awareness matters.

  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • Kamada Ltd.

GlobalData Eagle Pharmaceuticals Inc reported one pharmaceuticals & healthcare deal in YTD 2018.

  • Healthcare
  • Pharmaceutical
  • United States
  • Company Financials
  • Eagle Pharmaceuticals, Inc.
  • follicle stimulating hormone biobetter - Drug Profile
  • Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology - Drug Profile

Similarly, the Universities' portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Biosimilar
  • Healthcare
  • Urology
  • World
  • Cadila Healthcare Ltd
  • RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS - PIPELINE BY NEURACLE SCIENCE CO LTD, H2 2019

PALIVIZUMAB BIOBETTER(NS-##) EXERTS NEUTRALIZING AND FUSION-INHIBITORY EFFECT AGAINST RSV.

  • Healthcare
  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • Vaccine

ALPHA-## AWARENESS MATTERS.

  • Healthcare
  • United States
  • Company
  • Product Initiative
  • Kamada Ltd.
  • SFR-9350 - DRUG PROFILE

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical and Unknown stages are ##, ##, ##, ##, ##, ## and ## respectively.

  • Arthritis
  • Healthcare
  • Musculoskeletal Disorder
  • China
  • Selecta Biosciences, Inc.
  • WOMEN'S HEALTH DRUGS MARKET, GLOBAL, ALL PIPELINE PRODUCTS, 2018 (PART 1)

Reproductive BioMedicine Online; ## (supplement ##): ##-## OWH (2017).

  • Healthcare
  • OTC
  • Therapy
  • Company Financials
  • Forecast
  • Research and Development Brief
  • WOMEN INFERTILITY - DORMANT PROJECTS, H1 2018 (CONTD..1), H1 2018

FOLLICLE STIMULATING HORMONE (FSH) BIOBETTER MAY INCREASE BOTH OOCYTE NUMBER AND QUALITY IN MANY DIFFERENT TYPES OF INFERTILITY.

  • Genitourinary System Disease
  • Healthcare
  • United States
  • Product Initiative
  • Bayer AG
  • MARZEPTACOG ALFA - DRUG PROFILE

Clearance ranged from ##. ## to ##. ## mL h(-##) kg(-##).

  • Healthcare
  • Therapy
  • United States
  • World
  • Product Initiative

Patients were randomized to one of the three treatment groups (##:##:##) and the trial recruited patients in both the United States and Canada.

  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • Soligenix, Inc.
  • BCD-800 - DRUG PROFILE

To date, one partial response and one mixed response has been observed.

  • Digestive System Disorder
  • Healthcare
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genzyme Corp, H2 2019
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by HanAll Biopharma Co Ltd, H2 2019

The company develops drugs in therapeutic areas of ophthalmology, immunology, cardiovascular disease, dermatology and biobetter.

  • Autoimmune Disease
  • Healthcare
  • United States
  • Product Initiative
  • Rigel Pharmaceuticals, Inc.

The molecules developed by Companies in Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ##, ## and ## respectively.

  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • Kamada Ltd.

Immunogenicity: Of the ## patients, who completed ## year of treatment, three (##) male patients developed treatment induced IgG antibodies to pegunigalsidase alfa (ADA+); this comprised of two patients from Cohort ## (##. ## mg/ kg) and one from Cohort ## (## mg/

  • Healthcare
  • United States
  • World
  • Product Initiative
  • Amicus Therapeutics

It focuses on developing high-leveled mAb-based therapeutics, including mAb biosimilar, biobetters, mAb, biobetters, bispecific antibody drugs, and antibody drug conjugates among others.

  • Healthcare
  • Medical Biotechnology
  • United States
  • Company Operations
  • Product Initiative
  • BCD-600 - DRUG PROFILE

Patients were randomized to one of the three treatment groups (##:##:##) and the trial recruited patients in both the United States and Canada.

  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • Soligenix, Inc.